$294 Million is the total value of Summit Rock Advisors, LP's 7 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 150.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VT | Buy | VANGUARD INTL EQUITY INDEX Ftt wrld st etf | $133,230,000 | +30.3% | 1,369,410 | +24.0% | 45.26% | +26.9% |
| IUSV | Buy | ISHARES TRcore s&p us vlu | $50,999,000 | +12.9% | 740,195 | +1.9% | 17.32% | +10.0% |
| IWM | New | ISHARES TRrussell 2000 etf | $33,712,000 | – | 152,585 | +100.0% | 11.45% | – |
| VTV | New | VANGUARD INDEX FDSvalue etf | $31,262,000 | – | 237,808 | +100.0% | 10.62% | – |
| FROG | New | JFROG LTD | $447,000 | – | 10,079 | +100.0% | 0.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ISHARES TR | 29 | Q3 2020 | 90.6% |
| ISHARES TR | 26 | Q4 2020 | 51.7% |
| ISHARES INC | 11 | Q1 2020 | 64.0% |
| ISHARES TR | 11 | Q4 2021 | 47.6% |
| ISHARES TR | 9 | Q2 2015 | 34.5% |
| PHATHOM PHARMACEUTICALS INC | 9 | Q2 2022 | 1.1% |
| ISHARES TR RUS 2000 VAL ETF | 7 | Q4 2022 | 47.0% |
| SELECT SECTOR SPDR TR ENERGY | 6 | Q3 2023 | 67.4% |
| VANGUARD INTL EQUITY INDEX F | 5 | Q3 2022 | 45.3% |
| VANGUARD INDEX FDS | 4 | Q4 2021 | 36.4% |
View Summit Rock Advisors, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-01-26 |
| 13F-HR | 2023-10-24 |
| 13F-HR | 2023-07-21 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-01-12 |
| 13F-HR | 2022-11-02 |
| 13F-HR | 2022-08-01 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-10-26 |
View Summit Rock Advisors, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.